Prognostic significance of serum soluble CD163 level in patients with epithelial ovarian cancer.
The purpose of this study was to investigate the prognostic significance of serum sCD163 in patients with epithelial ovarian cancer. Preoperative serum samples from 55 patients with epithelial ovarian cancers were analyzed for sCD163 using a commercially available enzyme-linked immunosorbent assay kit. A Cox proportional hazard model was used to calculate hazard ratio (HR) and 95% confidence interval (CI) for disease-free survival (DFS) and overall survival (OS). Median serum sCD163 levels were higher in patients with a high-grade tumor. High serum sCD163 levels (3.43 mg/l) were associated with poor prognostic factors such as advanced stage (p = 0.024) and positive peritoneal cytology (p = 0.015). Univariate survival analysis showed that elevated sCD163 levels were associated with short DFS (8.0 vs. 32.4 months, p = 0.04) and OS (19.7 vs. 40.0 months, p = 0.027). Multivariate survival analysis revealed that high serum sCD163 levels were negatively associated with DFS (HR 3.1, 95% CI 1.2-8.1, p = 0.039). Our study shows that elevated serum sCD163 levels were associated with poor prognosis in patients with ovarian cancer. The prognostic significance of serum sCD163 in patients with epithelial ovarian cancer is described.